Toronto - Delayed Quote CAD

Knight Therapeutics Inc. (GUD.TO)

6.02
+0.02
+(0.33%)
At close: June 9 at 4:00:00 PM EDT
Currency in CAD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
372,776
371,304
328,199
293,563
243,478
Cost of Revenue
205,204
196,899
175,547
155,502
128,066
Gross Profit
167,572
174,405
152,652
138,061
115,412
Operating Expense
168,372
167,008
146,282
155,121
128,244
Operating Income
-800
7,397
6,370
-17,060
-12,832
Net Non Operating Interest Income Expense
1,221
1,187
87
4,032
3,764
Other Income Expense
8,376
-6,532
-28,445
-30,932
15,758
Pretax Income
8,797
2,052
-21,988
-43,960
6,690
Tax Provision
-2,266
-2,280
-5,153
-14,068
-8,985
Net Income Common Stockholders
11,063
4,332
-16,835
-29,892
15,675
Diluted NI Available to Com Stockholders
11,063
4,332
-16,835
-29,892
15,675
Basic EPS
0.10
--
-0.16
-0.26
0.13
Diluted EPS
0.10
--
-0.16
-0.26
0.13
Basic Average Shares
100,657.54
--
107,465.98
114,890.25
124,480.26
Diluted Average Shares
101,163.19
--
107,465.98
114,890.25
124,521.64
Total Operating Income as Reported
-800
7,397
-2,890
-41,044
-12,832
Total Expenses
373,576
363,907
321,829
310,623
256,310
Net Income from Continuing & Discontinued Operation
11,063
4,332
-16,835
-29,892
15,675
Normalized Income
3,571.10
9,774.55
7,179.10
-6,121.24
4,186.95
Interest Income
9,623
10,410
12,575
10,632
7,382
Interest Expense
8,402
9,223
12,488
6,600
3,618
Net Interest Income
1,221
1,187
87
4,032
3,764
EBIT
17,199
11,275
-9,500
-37,360
10,308
EBITDA
69,311
64,384
40,897
25,261
58,223
Reconciled Cost of Revenue
196,049
188,145
170,190
144,623
121,327
Reconciled Depreciation
52,112
53,109
50,397
62,621
47,915
Net Income from Continuing Operation Net Minority Interest
11,063
4,332
-16,835
-29,892
15,675
Total Unusual Items Excluding Goodwill
8,814
-6,403
-31,350
-34,957
15,630
Total Unusual Items
8,814
-6,403
-31,350
-34,957
15,630
Normalized EBITDA
60,497
70,787
72,247
60,218
42,593
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
1,322.10
-960.45
-7,335.90
-11,186.24
4,141.95
12/31/2021 - 3/3/2014

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

CPH.TO Cipher Pharmaceuticals Inc.
12.77
-3.62%
 
BHC.TO Bausch Health Companies Inc.
6.66
+1.99%
 
MDP.TO Medexus Pharmaceuticals Inc.
2.8400
0.00%
 
HLS.TO HLS Therapeutics Inc.
4.9800
+1.22%
 
HASH.V SIMPLY SOLVENTLESS CONCENTRATES
0.2000
+8.11%
 
CTX.TO Crescita Therapeutics Inc.
0.4800
+2.13%
 
ROMJ.V Rubicon Organics Inc.
0.4300
+1.18%
 
RX.V BioSyent Inc.
11.95
0.00%
 
CRON.TO Cronos Group Inc.
2.6700
-1.84%
 
CL.CN Cresco Labs Inc.
0.7300
-2.67%